Form D · Biotechnology
Hoth Therapeutics, Inc.
New York, NY · CIK 0001711786
Offering snapshot reported Jan 4, 2023 · SEC filing
- Reported sold
- $10M Offering amount: $10M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 3, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 4, 2023 | Initial | $10,000,000 | No comparison | 1 | SEC filing |
| Mar 16, 2021 | Initial | $15,000,000 | No comparison | 13 | SEC filing |
| Jan 8, 2021 | Initial | $5,000,000 | No comparison | 3 | SEC filing |
| Aug 21, 2019 | Initial | $2,037,120 | No comparison | 53 | SEC filing |
| Nov 7, 2017 | Initial | $1,000,000 | No comparison | 5 | SEC filing |
| Jul 14, 2017 | Initial | $675,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $700K
- Finders' fees
- $0
- Form D file number
- 021-469705
Represents a fee of 7% of the gross proceeds from the sale of securities. Excludes (i) a management fee of $100,000; (ii) non-accountable expenses of $20,000; (iii) accountable expenses of $50,000; and (iv) 100,000 placement agent warrants.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co., LLC | 375 |
Source: Form D, filed Jan 4, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Briones | Executive |
| Anthony Hayes | Director |
| Stefanie Johns | Executive |
| Robb Knie | Director, Executive |
| Wayne Linsley | Director |
| Vadim Mats | Director |
| Jeff Pavell | Director |
| Kenneth Rice | Director |
| David Sarnoff | Director |
| Graig Springer | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1 Rockefeller Plaza Suite 1039
New York, NY, 10020
New York, NY, 10020